• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Nominees for best AbbVie blunder in the last 10 years are…













Allergan integration. Ring fencing some areas but integrating others was a total mess. Two class system that keeps no one happy.

Key people within the ring fence left without a deep bench to replace them. R&D is now run by device people who worked on fillers but are now responsible for neurotoxin drugs. Who thought that would work?

Then you have the other areas that were critical to ensure the ring fenced business could thrive that were integrated into the Abbott/AbbVie machine. These technical experts were pushed out by incompetent AbbVie leaders. CMC being the most egregious.

This is a top blunder by far and we are still paying the price.
 
















Allergan integration. Ring fencing some areas but integrating others was a total mess. Two class system that keeps no one happy.

Key people within the ring fence left without a deep bench to replace them. R&D is now run by device people who worked on fillers but are now responsible for neurotoxin drugs. Who thought that would work?

Then you have the other areas that were critical to ensure the ring fenced business could thrive that were integrated into the Abbott/AbbVie machine. These technical experts were pushed out by incompetent AbbVie leaders. CMC being the most egregious.

This is a top blunder by far and we are still paying the price.


Could not agree more. The Allergan fools are DESTROYING the Company. Allergan/Forrest, etc. Forrest was the most corrupt in the field years ago, and nothing has changed. Look at the "leaders" we got from that "merger".
 




















Not exactly impressed with our new executive leadership team. They couldn’t identify a good pipeline if it bit them in the ass.
Is this too soon? The pipeline is crap. R&D is a mess - the entire leadership needs to be shown the door. Everybody knows that. But the new CEO needs to be given a grace period before judging him. I am hopeful that change is coming.
 












What about the huge influx of consultants, who have no prior drug development experience, are now teaching those in the fields for years about how to develop drugs, transform and innovate. They brand themselves problem solver and out of the box thinker. Well, it’s because they have never been in a box to know how a box actually work!
 




Talent selection, talent retention by far biggest blunder which is often offset by AbbVie’s financial capability to hire lots of talent and sometimes (not often enough) get it right. If AbbVie was better at selecting the right people to grow in the company and retaining the right talent, this company could be so much more successful.
 








Talent selection, talent retention by far biggest blunder which is often offset by AbbVie’s financial capability to hire lots of talent and sometimes (not often enough) get it right. If AbbVie was better at selecting the right people to grow in the company and retaining the right talent, this company could be so much more successful.
Insightful. I nearly accepted a role at Abbvie back in the Humira heyday, because I wanted to get back to the Chicago area. I walked away mainly due to the non-compete, but what you say was also quite obvious to any external recruit paying attention to more than just money. The vibe was that they were just looking for warm bodies (even at fairly senior levels), they would figure out the other stuff later.
 




Insightful. I nearly accepted a role at Abbvie back in the Humira heyday, because I wanted to get back to the Chicago area. I walked away mainly due to the non-compete, but what you say was also quite obvious to any external recruit paying attention to more than just money. The vibe was that they were just looking for warm bodies (even at fairly senior levels), they would figure out the other stuff later.

And yet here you are